Chemotherapy drugs that target cancer cells without damaging normal cells remain one of the key goals of precision medicine ...
Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer. At the 2025 IASLC World ...
Ibtrozi (taletrectinib) is approved for ROS1-positive NSCLC, showing high efficacy in TRUST-I and TRUST-II trials. Treatment-naive patients had response rates of 90% and 85%, with significant duration ...
ROS-mediated PKCζ S-glutathionylation at Cys48 is essential for LKB1 cytoplasmic localization and AMPK activation upon energy stress. AMP-activated protein kinase (AMPK) plays a central role in ...
16don MSN
Inflammation and metabolic stress combine to drive a new cell death pathway—mitoxyperilysis
In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback